Table 2.

Virologic and immunologic characteristics of participants following treatment interruption, stratified by study arm.

Characteristics	VHMa ​+ ​ARTb (N ​= ​9)	ARTb only (N ​= ​5)	p
Weeks from treatment interruption to viral load detection, ≥ 20 copies/mL	3 (2–5)	3.1 (3–11)	0.61
Viral load at detection, copies/mL	222 (33–41,822)	156 (52–395)	0.39
Weeks from treatment interruption to viral load rebound, >1,000 copies/mL	4 (2–7)	5 (4–16)	0.36
Peak viral load prior to ART resumption, copies/mL	10,797 (2,823–75,084)	4,717 (1,614–31,264)	0.21
Weeks from viral load detection, ≥20 copies/mL, to ART resumption	1 (0.1–4.1)	2 (1–5.3)	0.22
Weeks from ART resumption to VL suppression, <20 copies/mL	2.9 (0.9–10.9)	2 (1.9–3.9)	0.29
CD4+ T cells/μL change from study entry to ARTb resumption	2 (−376 to 549)	16 (−284 to 474)	0.74

Data are presented as Median (Minimum-Maximum).

^aVHM: vorinostat/hydroxychloroquine/maraviroc.

^bART: antiretroviral therapy.